Systems for treating post-traumatic stress disorder
US-2015374994-A1 · Dec 31, 2015 · US
US9669232B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9669232-B2 |
| Application number | US-201615015760-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 4, 2016 |
| Priority date | May 22, 2012 |
| Publication date | Jun 6, 2017 |
| Grant date | Jun 6, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Magneto-electric nanoparticles in a subject interact with an external magnetic field to cause stimulation of neural networks in the subject. Electric signals in the neural network are coupled to magnetic dipoles induced in the nanoparticles to cause changes in electric pulse sequences of the subject's brain.
Opening claim text (preview).
We claim: 1. A system for non-invasively stimulating a neural network in a subject brain, the system comprising: an injectable solution for intravenous introduction into the subject, the solution including nanoparticles formed from a multiferroic material, the nanoparticles not being associated with a therapeutic agent; and a low-energy magnetic field source configured to cause an alternating current magnetic field directed toward the subject to interact with the nanoparticles to induce local electric charge oscillations in the nanoparticles, which oscillations interact with the neural network causing neurons in the region of the oscillations to fire at frequencies similar to the frequency of the oscillation. 2. A system according to claim 1 , wherein the injectable solution is an aqueous solution. 3. A system according to claim 1 , wherein the multiferroic material comprises magneto-electric material. 4. A system according to claim 1 , wherein the injectable solution comprises a concentration of nanoparticles of 3×10 6 nanoparticles per cubic centimeter. 5. A system according to claim 1 , wherein the low-energy magnetic field source comprises an electromagnetic coil. 6. A system according to claim 1 , wherein the low-energy magnetic field source is operable to focus the magnetic field on a specific region of the subject brain. 7. A system according to claim 6 , wherein the low-energy magnetic field source is operable to focus the magnetic field on (a) the thalamic area; (b) the subthalamic nucleus; (c) the globus pallidus; or (d) the medial globus pallidus. 8. A system according to claim 7 , wherein the low-energy magnetic field source is configurable to output the alternating current magnetic field with a frequency selected according to a frequency associated with electric signals in the focused region of the subject brain. 9. A system according to claim 1 , wherein the low-energy magnetic field source is configurable to output the alternating current magnetic field with a frequency selected according to a frequency associated with electric signals in a region of the subject brain. 10. A system according to claim 1 , wherein the low-energy magnetic field source is operable to output an alternating current magnetic field having an amplitude of 300 Oe to interact with the nanoparticles. 11. A system according to claim 1 , wherein the injectable solution comprises nanoparticles having a magneto-electric coefficient of 100 V cm −1 Oe −1 . 12. A system according to claim 1 , wherein the injectable solution comprises nanoparticles of 20 nm in size. 13. A system according to claim 1 , wherein the injectable solution comprises nanoparticles less than 50 nm in size. 14. A system according to claim 1 , wherein the injectable solution comprises nanoparticles formed by Ion Beam Proximity Lithography. 15. A system according to claim 1 , wherein the low-energy magnetic field source is operable to generate the alternating current magnetic field with a frequency of 80 Hz. 16. An injectable solution for intravenous introduction into a subject, the solution comprising nanoparticles formed from a multiferroic material, the nanoparticles not being associated with a therapeutic agent and being smaller than 50 nm in size. 17. An injectable solution according to claim 16 , wherein the nanoparticles have a magneto-electric coupling coefficient of 100 V cm −1 Oe −1 . 18. An injectable solution according to claim 16 and having a concentration of nanoparticles between 0 and 10 7 particles per cubic centimeter. 19. An injectable solution according to claim 18 , wherein the concentration of nanoparticles is 3×10 6 particles per cubic centimeter. 20. An injectable solution according to claim 16 , wherein the nanoparticles are 20 nm in size. 21. An injectable solution according to claim 16 , wherein the nanoparticles are formed by Ion Beam Proximity Lithography.
for magnetic stimulation of nerve tissue · CPC title
Applying electric fields by inductive or capacitive coupling (microwave apparatus A61N5/00); {Applying radio-frequency signals} · CPC title
Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use (preparation of fullerenes in general C01B32/15) · CPC title
using magnetic fields produced by coils, including single turn loops or electromagnets (A61N2/12 takes precedence) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.